Illumina
Illumina, Inc. is an American biotechnology enterprise that develops, manufactures, and markets life science systems and integrated tools for genetic analysis. The company structures its business operations through primary reportable business segments, led by Core Illumina and specialized genomic diagnostics divisions. Its technical product portfolio comprises high-throughput DNA sequencing platforms, microarrays, sequencing chemistry consumables, and genomic data analysis software. Principal revenue drivers consist of high-margin recurring sales of sequencing consumables and reagents, system hardware sales of sequencers like NovaSeq, and technical service support. Illumina serves broad global health end markets including academic research centers, biopharmaceutical companies, clinical diagnostic laboratories, oncology clinics, and agricultural research institutes in over 150 countries. The corporation holds a dominant global market position as the primary provider of next-generation sequencing (NGS) technology and instruments worldwide. Headquartered in San Diego, California, the company's common stock is publicly listed on the Nasdaq Global Select Market under the ticker symbol ILMN and is included in the S&P 500 index.
75 of the funds FundTelligence covers report a position in Illumina.
- Legal name
- Illumina Inc.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 75
- Exposure themes
- Genomics & Profiling, Precision Medicine & Genomics, Sequencing
Funds holding Illumina
- Baillie Gifford Worldwide Positive Change Fund — Baillie Gifford · 5.72 % (full portfolio disclosed, September 2026)
- Allianz Global Equity Insights — Allianz Global Investors · 2.53 % (largest positions only, September 2026)
- Pensum Kairos — Pensum · 2.33 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 2.07 % (full portfolio disclosed, October 2026)
- Templeton Global Smaller Companies Fund — Franklin Templeton · 1.99 % (full portfolio disclosed, September 2026)
- Delphi Global — Storebrand · 1.61 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.56 % (full portfolio disclosed, October 2026)
- Nordea Global Consumer Trends — Nordea Funds · 1.26 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 75 funds holding it.